A CLAIMS DATA ANALYSIS OF BIOLOGICAL AGENTS FOR PSORIATIC ARTHRITIS IN GERMANY

Vollmer L1, Schlechta W2, Rex J1, Wolter S3

1 M&G Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany
2 University of Applied Sciences, Rotenburg-Necker, Germany
3 Elevator Health Analytics, Berlin, Germany

STATE UNIVERSITY BADEN-WUERTTEMBERG, LOEN, Germany

BACKGROUND:
- Approximately 3% of patients with Psoriasis are developing Psoriatic arthritis (PsA).
- This study provides information on the current supply with biological agents and its related costs (other medication, outpatient care, hospital admissions) in Germany.

METHODS:
- The design is a retrospective claims data analysis.
- The data source is the database of the Institute for Applied Health Research (InGesOr Berlin, formerly IPH/Health Halle Institute, which includes approximately 4.7 million insured anonymized who originate from 83 statutory health insurances in Germany. The observation period was from 2012 to 2016 and analyses were performed by the InHealth Institute. A sample with approximately 4 million insured persons was drawn and stratified by age and gender according to the official demographic structure of the German statutory health insured population (Destatis, Dec 31st, 2013).
- The target population consists of patients who met following criteria with regard to the observation period from 2012 to 2016:
  1. Main diagnosis of PSA (using relevant ICD-10 codes according to Table 1).
  2. Patients who get continuous treatment with the same biological agent.
  3. Patients who switch biological (“Switcher”).
- In sum, 1.545 patients could be included in the sample.

RESULTS:
- Most patients with PsA are aged above 46, thereby the proportion below 17 years’ account for less than 1%. The average age of all age cohorts is 50.8 years, with the subgroup of men slightly younger than women (49.0 yr men vs. 52.7 yr women).
- The distribution of men and women is almost the same (49.9% male vs. 50.1% female) (see also Figure 2).

CONCLUSIONS:
- Adalimumab and etanercept are administered mostly to patients who are already on treatment in 2015 adalimumab 38.3 % vs. etanercept 31.3 %.

REFERENCES:
3. EMA, April 2017.